Declaration of interests N.N.S reports participation in advisory boards and/or consultancy for Kite Pharma, TG Therapeutics, Miltenyi Biotec, Lilly, Epizyme, Legend, Incyte, Novartis, and Umoja, as well as research funding and honoraria from Miltenyi Biotec. T.S.F reports research funding from Novartis, Portola, Curis, and TG Therapeutics and consultancy and/or speaking for Adaptive Biotechnologies, ADC Therapeutics, AbbVie/ Pharmacyclics, AstraZeneca, Beigene, Bristol-Myers Squibb, Biogen, CSL Therapeutics, KaryoPharm, Kite (Gilead), MorphoSys, Pharmacyclics, Sanofi, Servier Pharmaceuticals, TG Therapeutics, Kyowa, and Veristem. A.D. has served on the advisory boards of BMS and Pfizer, and she reports consultancy for Janssen, travel support from Imbrium, and research support and/or funding from Janssen, TNB-383B, Abbvie, Regeneron, Takeda, Sanofi, Prothena, and Caelum (Funding to Institution for Clinical Trial). B.D. reports honoraria from and/or consultancy for BMS, Karyopharm, GSK, Janssen, Arcellx, Genetech, Natera, Sanofi, Takdea, and Amgen, as well as research funding from Amgen, Sanofi, Arcellx, Carsgen, Cartesian, Fate, Janssen, and BMS. S.C. reports research funding from Amgen, Janssen, Sanofi, and Syndax and has served on the advisory boards of GSK and Sanofi. M.H. reports consultancy for Incyte Corporation, ADC Therapeutics, Magenta Therapeutics, Omeros, AbGenomics, MorphoSys, Kite, Novartis, GenMab, Seattle Genetics, Gamida Cell, Legend Biotech, and Kadmon and has served on speaker’s bureaus for Sanofi Genzyme, Astrazeneca, BeiGene, and ADC Therapeutics. The remaining authors declare no competing financial interests.